**When Dyspnea isn’t COVID**

References

* Marco JL, Collins BF. Clinical manifestations and treatment of antisynthetase syndrome. Best Pract Res Clin Rheumatol 2020;34(4):10153.
* Rojas-Serrano J, Herrera-Bringas D, Mejia M, Rivero H, Mateos-Toledo H, Figueroa JE. Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lunch disease (ILD). Clin Rheumatol 2015;34(9):1563-9.
* Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol 2011;37(1):100-9.
* Trallero-Araguas E, Grau-Junyent JM, Monteagudo M, et al. FR10463 Survival and Mortality Analysis in a Large Cohort of Spanish Patients with Anti-J01 Antisynthetase Syndrome from the GEAS-IIM Group. Annals of the Rheymatic Diseases 2015;74(Suppl 2):595-595.4.
* Witt LJ, Curran JJ, Strek ME. The Diagnosis and Treatment of Antisynthetase Syndrome. Clin Pulm Med 2016;23(5):218-26.